Patient Sex/age (y) at presentation Antecedent or synchronous lymphoma TNM stage Number of lesions treated with RT Location of lesion Date of completion of RT Clinical or pathologic diagnosis Histological type Immunophenotype Prior therapies Total dose (Gy)/dose per fraction/energy/ Response at RT site LR/follow-up (m) 1 M/48 n/a T3b 1 Right lower extremity 08/15/11 Path. n/s CD4+ /CD30+ Oral/IL methotrexate, topical imiquimod 8/8, 12 MeV e− , 1 cm bolus, 90% IDL CR N/16 2
M/60 Synchronous subcutaneous NHL
T3b
6 Left groin 12/26/02 Clin. CHOP × 6c 45/2.5, 10 MeV e− , 1 cm bolus, 90% IDL CR N/131 Right femoral region 12/26/02 Clin. 45/2.5, 10 MeV e− , 1 cm bolus, 90% IDL CR N/131 Right axilla 12/26/02 Path. C CD4+ /CD30+ 45/2.5, 10 MeV e− , 1 cm bolus, 90% IDL CR N/131 Left axilla 12/26/02 Clin. 45/2.5, 10 MeV e− , 1 cm bolus, 90% IDL CR N/131 Right neck 4/7/03 Path. n/s CD4+ /CD30+ 45/2.5, 10 MeV e− , 1 cm bolus, 90% IDL CR N/127 Right elbow 3/01/06 Clin. 45/2.5, 10 MeV e− , 1 cm bolus, 90% IDL CR N/99 3
F/83 Antecedent HL
T3b
2 Left lateral thigh 11/12/10 Path. n/s CD4+ /CD30+ IL methotrexate, IL triamcinolone acetonide 8/8, 10 MeV e− , 1 cm bolus, 95% IDL CR N/37 Left calf 09/07/11 Path. C CD4+ /CD30+ IL steroids 8/8, 12 MeV e− , 1 cm bolus, 90% IDL CR N/27 4 F/53 n/a T3a 1 Upper lip 10/21/99 Path. A n/s 42/2, 10 MeV e− , 0.5 cm bolus, 90% IDL CR N/146 5 F/34 n/a T3b 1 Left forearm 7/23/12 Path. C CD4+ /CD30+ Topical methotrexate, PUVA, triamcinolone acetonide 7.5/7.5, 12 MeV e− , 1 cm bolus, 90% IDL CR N/18 6 M/15 n/a T3b 1 Left back 9/28/08 Clin. RT, prednisone, minocycline 40/2, 12 MeV e− , 1 cm bolus, 95% IDL CR N/66
